Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
ConditionAtopic Dermatitis (AD)
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorEnveda Therapeutics
About this trial
The goal of this clinical trial is to learn about the safety and effectiveness of ENV-294 in adults with moderate to severe atopic dermatitis.
The main questions it will answer are:
* Is there an impact on the severity and area of atopic dermatitis when participants take ENV-294 * What medical problems do participants have when taking ENV-294
Participants will:
* Take drug ENV-294 or a placebo once every day for 12 weeks * Visit the clinic every 2 to 4 weeks for checkups and tests * Keep a diary of their symptoms and when they took their study drug * Return to the clinic for the final study visit at approximately week 16
Eligibility criteria
Qualifiers
Have chronic atopic dermatitis that was diagnosed at least 12 months prior to the first study visit
A vIGA score of 3 (moderate) or 4 (severe)
EASI score of ≥16
BSA ≥10%
Disqualifiers
Current or recurrent medical conditions that could affect the study drug or study assessments
Any illness that could impact participant safety or active infections
Ongoing skin condition or large tattoos that would interfere with clinical assessment
Clinically significant skin infection requiring treatment
Trial design
Treatments tested in this trial
- ENV-294
- Placebo
Treatment groups
60 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov